. Author manuscript; available in PMC: 2014 Nov 15.

Published in final edited form as: Clin Cancer Res. 2013 Oct 4;19(22):10.1158/1078-0432.CCR-13-1848. doi: 10.1158/1078-0432.CCR-13-1848

Table 3.

Patient response vs dose of bendamustine

Bendamustine Dose	70 mg/m²	90 mg/m²	Total
No. of patients	6	6	12
Standard criteria
CR	3 (50%)	4 (67%)^*	7 (58%)
PR	3 (50%)	2 (33%)	5 (42%)
ORR	6 (100%)	6 (100%)	12 (100%)
Time to CR (Median)	223 days	111 days	162 days
Time to CR (range)	213–328 days	56–112 days	56–328 days
Time to MRD-free (median)	153 days	112 days	112 days
Time to MRD-free (range)	82–223	110–112	82–223
Negative for minimal residual disease (MRD)
Bone marrow IHC	3 (50%)	4 (66%)	7 (58%)
Blood flow cytometry	4 (67%)	5 (83%)	9 (75%)
Marrow flow cytometry	2 (33%)	4 (67%)	6 (50%)

One of the 4 CRs had incomplete recovery of platelets (CRi).